-
Pharmaceutical companies are named again for sales with gold
Time of Update: 2021-04-23
According to the above article, Liu Feng, the second-level inspector of the Bureau of Supervision and Evaluation of the Ministry of Finance, summarized from three aspects: “After inspection, he found out the cause of the falsely high drug prices, and deterred the illegal behavior of pharmaceutical companies to sell money and drive up prices.
-
State Council: Let go of the prescription drug sales online!
Time of Update: 2021-04-23
(Ministry of Civil Affairs, National Health Commission, State Drug Administration and other relevant departments of the State Council and various regions are responsible according to the division of responsibilities) Among them, “on the premise of ensuring the authenticity and reliability of the source of electronic prescriptions, online sales of prescription drugs other than those under special state management are allowed.
-
Yuheng Pharmaceutical's Lugua Polypeptide was withdrawn from the Internet!
Time of Update: 2021-04-23
According to the requirements of the notice, since the date when the provincial medicine price and credit evaluation system for recruitment and procurement takes effect, pharmaceutical companies participating in or entrusting to participate in centralized procurement, online procurement, and filing procurement of drugs and medical consumables must submit a trustworthy commitment.
-
93 exclusive protected Chinese medicine varieties sold for 20 billion!
Time of Update: 2021-04-23
20 varieties of medical terminals sold over 100 million in half a year, and Naoxintong capsules won the first prize Table 3: Exclusive Chinese medicine protected varieties with sales exceeding 100 million yuan in 2020H1 Source: China Traditional Chinese Medicine Protected Varieties Catalog Database on Mynet According to data from Menet.
-
The drug dealer issued a notice: a "4+7" quantity-collected product, difficult to purchase
Time of Update: 2021-04-23
For example, Hubei announced that the national organization of centralized drug procurement pilot expansion (Hubei) paroxetine oral constant-release dosage form and other 8 varieties of selected results also include dexmedetomidine hydrochloride injection.
-
The fifth batch of centralized injections accounted for 50% of the four major cephalosporin antibiotics
Time of Update: 2021-04-23
cn/news/yyzb/" target="_blank">》，、。 ，35、、11，，，。 According to the normalized deployment of "centralized procurement twice a year", although biosimilar drugs and proprietary Chinese medicines have not yet appeared in the fifth batch of centralized procurement, whether it is the information released by the medical insurance bureau’s symposium or the normalized collection of the State Council From the perspective of opinions, it will be sooner or later that these types of products will be included in centralized procurement.
-
Announcement of annual results of Machinery Enterprise: Weigao, MicroPort, Yuyue...
Time of Update: 2021-04-23
2500%， ，iFinD，412，332020。 ，，2020，。 ，、，202047. 63，1203. 53%；26. 17，6527. 90%。 ，、、。 2020138. 37，564. 29%；70. 07，3829. 56%。，。 Previously, in the 2020 annual report performance forecast disclosed
-
Arnold Pharma announces the completion of the first patient dosing for Buparlisib's global phase III clinical trial
Time of Update: 2021-04-23
On April 15th, Arnold Pharma announced that its oral PI3K inhibitor Buparlisib (AN2025) combined with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in the global multi-center phase III clinical trial has been successful in Shanghai Oriental Hospital, China Complete the first patient's administration.
-
Pharmacies in Shanxi Province will resume sales of antipyretic drugs from April 16th
Time of Update: 2021-04-23
Medical Network News, April 19 Since April 16, pharmacies in Shanxi Province have resumed sales of antipyretic drugs. With immediate effect, pharmacies resume sales According to the "Notice on Str
-
The use rate of essential medicines is less than 70%, which affects the salary of primary doctors
Time of Update: 2021-04-23
According to a doctor at the grassroots level, the following problems are common in the use of medicine at the grassroots level:① The price of basic medicines in primary medical institutions is inflated and continues to rise, some even doubled, even more expensive than outside pharmacies.
-
Pfizer and Moderna refuse to cooperate with Johnson & Johnson on coagulation of the new crown vaccine
Time of Update: 2021-04-23
Compile Ke KeAccording to a recent report by the Wall Street Journal, Johnson & Johnson contacted Pfizer, Moderna and AstraZeneca to ask them to investigate the coagulation problem caused by the COVID-19 vaccine and "express opinions on safety issues.
-
To prepare for the fifth batch of national procurement, nine major pieces of information that companies must collect!
Time of Update: 2021-04-23
cn/news/yyzb/" target="_blank">。 ，，。 No matter what kind of response strategy an enterprise adopts, its foundation is to obtain accurate intelligence, especially information that is essential for making decisions.
-
"Decentralization, management and service" reform of outpatient fee settlement and other matters are expected to be handled across provinces during the year
Time of Update: 2021-04-23
cn/" target="_blank"> and regulations Regarding the reform of “delegation, regulation, and service” in investment approval, the National Development and Reform Commission will organize and carry out special supervision of administrative law enforcement in the investment field, and guide local governments to accelerate the implementation of the commitment system for enterprise investment projects.
-
AstraZeneca's diabetes drug Farxiga fails in COVID-19 study
Time of Update: 2021-04-23
Compile Ke KeOn April 12, AstraZeneca announced that its diabetes drug Farxiga (dapagliflozin) failed to reach the end point in a phase three study.
The DARE-19 study provides important data on the potential benefits and risks of using SGLT2 inhibitors to treat COVID-19 hospitalized patients.
-
Chengdu Better will win 11 first imitations of 8 billion large varieties!
Time of Update: 2021-04-23
32 new products focus on the 30 billion market, and 11 varieties are the first to imitate On April 1, Chengdu Better’s application for the listing of dapagliflozin tablets submitted for imitation of category 4 was accepted by CDE; on March 31, the company’s category 4 generic drug inhalation budesonide suspension entered the "under review".
-
Yuandong Double Happiness is here!
Time of Update: 2021-04-23
Yuandong Bio's Propofol Fumarate Tenofovir Tablets and Dabigatran Etexilate Capsules were approved for production on the same day.
Yuandong Bio's Propofol Fumarate Tenofovir Tablets and Dabigatran Etexilate Capsules were approved for production on the same day.
-
The fifth batch of national centralized drug procurement started the inclusion of multiple 1 billion-level large varieties
Time of Update: 2021-04-23
It is reported that this centralized procurement may involve 60 varieties and 207 product specifications, including tumor chemotherapy drugs, digestive preparations, antibiotics, inhalation preparations, contrast agents, diabetes drugs, ophthalmology-related drugs, antiviral drugs, etc.
-
License-in inventory for the first quarter!
Time of Update: 2021-04-23
Introduced party: Sidi MedicineAuthorized party: ImmuneOncia TherapeuticsMechanism of drug action: anti-CD47 monoclonal antibodyOn March 31st, Sidi Medicine announced that it has obtained the exclusive authorization for the development, production and commercialization of ImmuneOncia's new generation of anti-CD47 monoclonal antibody IMC-002 tumor indications in Greater China (Mainland China, Hong Kong, Macau and Taiwan).
-
National Food and Drug Administration: Guifu Dihuang Granules converted to non-prescription drugs
Time of Update: 2021-04-23
This product contains aconite (made)[Drug Name]Generic name: Guifu Dihuang GranulesChinese Pinyin:[Ingredients][Properties][Functions and Indications] Warming and nourishing kidney-yang.
If you are using other drugs, please consult your physician or pharmacist before using this product.
-
110 pharmaceutical companies posted their first quarter transcripts!
Time of Update: 2021-04-23
Three companies including Intech Healthcare and Daan Gene have net profits of over 1 billion yuan; 500 million to 1 billion yuan are Changchun High-tech, Yiling Pharmaceutical, 7 companies including China Resources Sanjiu and Harbin Sanlian; 52 companies including Kelun Pharmaceutical, Haisco and Zuoli Pharmaceutical have doubled, and Hotview Bio has soared 1,000 times, becoming the "pre-increasing king" of performance; Qianhong Pharmaceutical, 18 companies including Jinling Pharmaceutical turned losses into profits.
